Chiesi Group and Haisco Pharmaceutical Collaborate on New Bronchiectasis Treatment

Chiesi Farmaceutici Spa, also known as Chiesi Group, a global biopharmaceuticals and healthcare organization with a focus on research, has entered into a Licensing Agreement with Haisco Pharmaceutical Group Co. Ltd (Haisco Pharmaceutical). The agreement covers the collaborative development, manufacturing, and commercialization of HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor designed for respiratory diseases. This collaboration extends to regions outside China and adjacent territories, including Hong Kong SAR, Macau SAR, and Taiwan District.

Currently in Phase 2 trials in China, HSK31858 is an oral, potent, and highly selective small molecule DPP1 inhibitor with potential as an anti-inflammatory agent in bronchiectasis.

Chiesi's strategic objective is to expand its product portfolio in the respiratory field, reinforcing its commitment to addressing severe respiratory diseases with significant unmet medical needs.

Thomas Eichholtz, Head of Global Research and Development at Chiesi Group, expressed the company's dedication to developing innovative medicines that enhance the lives of patients facing limited treatment options. He emphasized the significance of HSK31858 as a valuable addition to Chiesi's pipeline and highlighted the opportunity for synergy between the partners' extensive experience in respiratory research.

Xiulian Fan, General Manager at Haisco Pharmaceutical, sees this collaboration as a pivotal step in their global expansion strategy. He expressed satisfaction that HSK31858 will eventually benefit patients worldwide. Fan acknowledged Chiesi's substantial commitment and expertise in respiratory drug development, anticipating that the partnership would maximize the value of HSK31858.

The agreement outlines an upfront payment from Chiesi to Haisco, along with contingent milestone payments, including royalties based on product sales.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!